Roche: posts positive lung cancer drug data
(CercleFinance.com) - A Phase III study showed that Roche's Tecentriq and Avastin plus chemotherapy helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin and chemotherapy alone, the Swiss drugmaker said.
This analysis showed that the combination helped people with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, having a median overall survival of 19.2 months, versus 14.7 months for the other group.
Roche also said that follow-up phase III data showed Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death.
Alecensa more than tripled median progression-free survival (34.8 months compared to 10.9 months for Pfizer's crizotinib), the group said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.